AorTech’s interim results show the strategy, focused on developing two growth platforms using Elast-Eon, is progressing well. Management has signed agreements with two partners to bring new medical textiles to market and to take a new polymeric heart valve towards commercialisation. There was still £2.6m of net cash at end September following the £2.6m fundraising in June 2018. There are no changes to any of our forecasts other than changing the reporting currency to sterlin
22 Nov 2018
Progressing in line with expectations
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Progressing in line with expectations
RUA Life Sciences Plc (RUA:LON) | 11.5 0 0.0% | Mkt Cap: 7.14m
- Published:
22 Nov 2018 -
Author:
Robert Sanders -
Pages:
2
AorTech’s interim results show the strategy, focused on developing two growth platforms using Elast-Eon, is progressing well. Management has signed agreements with two partners to bring new medical textiles to market and to take a new polymeric heart valve towards commercialisation. There was still £2.6m of net cash at end September following the £2.6m fundraising in June 2018. There are no changes to any of our forecasts other than changing the reporting currency to sterlin